What retatrutide is. And where it comes from
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly. Its scaffold is based on the GIP sequence, the same starting point as tirzepatide, but with additional modifications that confer glucagon receptor agonism, making it a triple incretin agonist. Four specific structural modifications are key: two non-coded amino acid substitutions (aminoisobutyric acid at positions 2 and 20, and 2-methylleucine at position 13) that resist enzymatic degradation, and a C20 fatty diacid side chain on a modified lysine at position 17 that enables albumin binding for a ~6-day half-life.
The cryo-EM structural analysis published in Cell Discovery (2024, PMID 39019866) revealed how a single peptide achieves triple receptor activation: receptor-specific conformations in the extracellular loop 1 (ECL1) region allow the same molecule to dock into three structurally distinct receptor binding pockets.
Retatrutide adds glucagon receptor agonism to the GIP + GLP-1 dual mechanism of tirzepatide. That third pathway directly increases energy expenditure and lipolysis, it is the mechanistic reason the weight loss numbers are larger than any dual agonist to date.
Mechanism, in plain English
Three receptor pathways activated simultaneously:
- GLP-1 receptor (GLP-1R). Expressed on pancreatic beta cells, hypothalamus, GI tract, heart, and kidneys. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, activates hypothalamic satiety centers.
- GIP receptor (GIPR). Expressed on beta cells, adipose tissue, bone, and brain. Potentiates insulin release synergistically with GLP-1R, exerts beta-cell pro-survival effects, modulates lipid handling.
- Glucagon receptor (GCGR). Expressed on hepatocytes, adipose tissue, kidneys, heart. Increases resting metabolic rate and thermogenesis, promotes lipolysis (fat breakdown), modulates hepatic glucose production. This is the pathway that distinguishes retatrutide from all prior approved incretin agents.
Crucially, the GCGR activation does not cause hyperglycemia in this context because the concurrent GLP-1R and GIPR activation enhances insulin secretion simultaneously. The net effect is increased metabolic rate without the glucose elevation that would occur with glucagon alone.
What the trial evidence shows
Phase 2 (NEJM 2023). Jastreboff et al., NEJM 2023, PMID 37366315. 338 adults with obesity, 48-week treatment:
At the 12 mg dose, mean weight loss was 24.2% at 48 weeks. 93% of participants achieved ≥10% weight loss; 83% achieved ≥15%. No prior pharmacological obesity trial had reported these figures.
Phase 3 TRIUMPH program. Eight pivotal trials enrolling ~5,800 participants, completing 2025-2026. Key results announced:
- TRIUMPH-1 (obesity/overweight, 80 weeks): Mean weight loss 28.3% at 12 mg. 45.3% of participants achieved ≥30% weight loss. Approaching bariatric surgery outcomes.
- TRIUMPH-2 (obesity + type 2 diabetes, 80 weeks): Mean weight loss 20.8% at 12 mg with significant HbA1c reduction.
- TRIUMPH-3 (severe obesity + cardiovascular disease, 80 weeks): Up to 22.6% weight loss.
- TRIUMPH-4 (obesity + knee osteoarthritis, 68 weeks): 28.7% weight loss at 12 mg.
Network meta-analysis vs tirzepatide. A systematic network meta-analysis (PMC 2025) found retatrutide superior to tirzepatide: -23.77% vs -16.79% weight loss (p < 0.0001), with higher but manageable adverse event burden (RR 4.10 vs 2.78).
FDA status (this month)
Retatrutide is an investigational drug. As of August 2026 it is not approved by the FDA, EMA, or any major regulatory authority. Eli Lilly has announced plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 based on the TRIUMPH phase 3 program results. Last reviewed 2026-08-16.
Common synonyms researchers use
Retatrutide · LY3437943 · LY-3437943 · GLP-1/GIP/glucagon triple agonist · triple incretin agonist · NOP2Y096GV (FDA UNII)
Safety & adverse-event landscape
Most common adverse events in phase 2 and phase 3 trials are gastrointestinal and dose-dependent: nausea (14-60%), vomiting (3-26%), diarrhea (9-33%), constipation (9%), decreased appetite (18%). Events follow the same pattern as other incretin agents, most occur during dose escalation and attenuate with continued exposure. Discontinuation due to adverse events: 6-16% across dose groups vs near-zero in placebo.
Cardiovascular effects: systolic blood pressure decreased by a mean of 9.88 mmHg and diastolic by 3.88 mmHg. The product class carries the same thyroid C-cell tumor boxed warning as other GLP-1 receptor agonists based on rodent carcinogenicity data. Always consult a qualified healthcare provider.
Frequently asked questions
Want all 24 weight loss and metabolism compounds in one place?
The Peptexa Weight Loss and Metabolism guide covers retatrutide, tirzepatide, semaglutide, and 21 more compounds, mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Weight Loss & Metabolism reference
24 compounds including all triple/dual incretin agonists. Mechanism, evidence level, and FDA status for every one. Free PDF, no email required.
Get the Weight Loss & Metabolism Guide →